Yazar "Kilickap, S." seçeneğine göre listele
Listeleniyor 1 - 13 / 13
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1(Elsevier Science Inc, 2021) Bondarenko, I.; Sezer, A.; Kilickap, S.; Gumus, M.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC(Elsevier Science Inc, 2021) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey(Elsevier Science Inc, 2018) Kilickap, S.; Ozturk, A.; Karadurmus, N.; Korkmaz, T.; Yumuk, P.; Cicin, I.; Paydas, S.[Abstract Not Available]Öğe The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey(Oxford Univ Press, 2018) Kilickap, S.; Olmez, O. F.; Cicin, I.; Demirci, U.; Alan, O.; Cabuk, D.; Sakalar, T.[Abstract Not Available]Öğe EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients ( pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%-3-year update(Elsevier Science Inc, 2023) Kilickap, S.; Ozguroglu, M.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%(Elsevier, 2020) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients [Meeting Abstract](Elsevier Science Inc, 2021) Peled, N.; Gillis, R.; Kilickap, S.; Froesch, P.; Orlov, S.; Filippova, E.; Demirci, U.[Abstract Not Available]Öğe The impact of everolimus on pulmonary damage with radiotherapy: Results of an experimental study(Elsevier Sci Ltd, 2015) Eren, M.; Eren, A. Ay; Yucel, B.; Ozguven, Y.; Matsuno, R. K.; Altun, A.; Kilickap, S.[Abstract Not Available]Öğe The impact of everolimus on radiation-induced pulmonary fibrosis in wistar albino rats: Results of an experimental study(Amer Assoc Cancer Research, 2016) Eren, M. F.; Eren, A. Ay; Yucel, B.; Elagoz, S.; Ozguven, Y.; Altun, A.; Kilickap, S.[Abstract Not Available]Öğe Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?(Oxford Univ Press, 2019) Kilickap, S.; Basal, F. Bugdayci; Demirkazik, A.; Gursoy, P.; Demirci, U.; Erman, M.; Yumuk, F.[Abstract Not Available]Öğe Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey(Elsevier Science Inc, 2019) Kilickap, S.; Demirci, U.; Bugdayci, F.; Tural, D.; Korkmaz, T.; Paydas, S.; Yilmaz, C.[Abstract Not Available]Öğe Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial(Elsevier, 2022) Ho, G. F.; Ozguroglu, M.; Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.[Abstract Not Available]Öğe Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression plus Chemotherapy: EMPOWER-Lung 1(Elsevier Science Inc, 2023) Garassino, M. C.; Kilickap, S.; Ozguroglu, M.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.[Abstract Not Available]
